About 10% of Americans have Type 2 diabetes (T2), often along with obesity and heart disease. As treatment strategies evolve, GLP-1 receptor agonists have emerged as a widely adopted therapeutic option.
Our latest analysis reveals how the characteristics and expectations of people with T2 embarking on GLP-1 therapy have evolved over the last three years, highlighting key trends shaping today’s treatment landscape.
Download the poster for a closer look at the methodology, results, and conclusions of this study.
dQ&A presented three research abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA), the world’s largest diabetes conference.
Read More
This research excerpt is just the tip of the iceberg. dQ&A has decades of experience across the United States, Canada, and Europe. If you drive critical diabetes research decisions in your organization, dQ&A is the diabetes insight partner that can get the answers you need.
